Hollis-Eden - Worst Pharma Stocks of 2007

Company: Hollis-Eden Pharmaceuticals
Starting stock price: $5.22
Ending stock price: $1.57
Percent Change: -69.92%

Details: On March 7, Hollis-Eden received some really bad news: a highly-anticipated contract with the Department of Health and Human Service was not going to materialize. The agency decided not to buy into Neumune, a therapy for acute radiation syndrome and a prime candidate for stockpiling under the government’s Project BioShield. Hollis-Eden's stock lost a third of its value and not long after, a quarter of the company's staff was laid off. In recent months, however, the company has been mounting a come-back, reporting impressive preclinical data. 

More News:
Hollis-Eden spurs stock price with preclinical news. Report
Hollis-Eden skyrockets on preclinical cancer data. Report
Hollis-Eden to chop work force in restructuring. Report
Hollis-Eden shares plunge on HHS drug rejection. Report

Hollis-Eden - Worst Pharma Stocks of 2007
Read more on

Suggested Articles

Bluebird Bio has overcome a manufacturing hiccup that looked like it would delay its gene therapy launch in Europe until next year.

Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.

GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.